LIFE:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund Hedged Units (CAD)

ETF | Sector Equity |

Last Closing

CAD 21.98

Change

+0.12 (+0.55)%

Market Cap

CAD 0.21B

Volume

6.84K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

+0.14 (+0.35%)

CAD 2.88B
TEC:CA TD Global Technology Leaders I..

+0.14 (+0.35%)

CAD 2.88B
ZWU:CA BMO Covered Call Utilities ETF

N/A

CAD 1.94B
ZWU:CA BMO Covered Call Utilities ETF

N/A

CAD 1.94B
XHC:CA iShares Global Healthcare (CAD..

+0.21 (+0.28%)

CAD 0.65B
XHC:CA iShares Global Healthcare (CAD..

+0.21 (+0.28%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+0.49 (+0.85%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+0.49 (+0.85%)

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

N/A

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

N/A

CAD 0.65B

ETFs Containing LIFE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.72% 21% F 36% F
Dividend Return 1.54% 56% F 39% F
Total Return 7.26% 24% F 35% F
Trailing 12 Months  
Capital Gain 7.59% 13% F 28% F
Dividend Return 1.57% 52% F 32% F
Total Return 9.15% 10% F 28% F
Trailing 5 Years  
Capital Gain 15.44% 19% F 47% F
Dividend Return 6.64% 43% F 22% F
Total Return 22.09% 16% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 0.96% N/A N/A 40% F
Dividend Return 2.08% N/A N/A 39% F
Total Return 1.13% N/A N/A 39% F
Risk Return Profile  
Volatility (Standard Deviation) 6.94% N/A N/A 57% F
Risk Adjusted Return 30.04% N/A N/A 49% F
Market Capitalization 0.21B 60% D- 47% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.